期刊论文详细信息
Toxins
Botulinum Toxin: An Update on Pharmacology and Newer Products in Development
Suparna Chatterjee1  Supriyo Choudhury1  Hrishikesh Kumar1  MarkR. Baker2 
[1] Department of Neurology, Institute of Neurosciences Kolkata, Kolkata 700017, India;Departments of Neurology and Clinical Neurophysiology, Royal Victoria Infirmary, Queen Victoria Rd, Newcastle upon Tyne NE1 4LP, UK;
关键词: botulinum toxin;    dystonia;    recombinant botulinum toxin;    acetylcholine;    neuromuscular blockade;   
DOI  :  10.3390/toxins13010058
来源: DOAJ
【 摘 要 】

Since its introduction as a treatment for strabismus, botulinum toxin (BoNT) has had a phenomenal journey and is now recommended as first-line treatment for focal dystonia, despite short-term clinical benefits and the risks of adverse effects. To cater for the high demand across various medical specialties, at least six US Food and Drug Administration (FDA)-approved formulations of BoNT are currently available for diverse labelled indications. The toxo-pharmacological properties of these formulations are not uniform and thus should not be used interchangeably. Synthetic BoNTs and BoNTs from non-clostridial sources are not far from clinical use. Moreover, the study of mutations in naturally occurring toxins has led to modulation in the toxo-pharmacokinetic properties of BoNTs, including the duration and potency. We present an overview of the toxo-pharmacology of conventional and novel BoNT preparations, including those awaiting imminent translation from the laboratory to the clinic.

【 授权许可】

Unknown   

  文献评价指标  
  下载次数:0次 浏览次数:2次